Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
Shao, Jingwei , Yan, Yuqian , Ding, Donglin , Wang, Dejie , He, Yundong , Pan, Yunqian , Kharbanda, Anupreet , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei

Mayo Clinic

Advanced Science | August 16, 2021 | Volume: 8 | Issue: 20 | Pages: No page available

10.1002/advs.202102555 | PMID 34397171 Get It

AbstractDNA‐binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand‐binding pocket. Proteolysis‐targeting chimera (PROTAC) technology has been developed by engineering a bifunctional molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through the proteasome pathway. Here, the development of oligonucleotide‐based PROTAC (O'PROTACs), a class of noncanonical PROTACs in which a TF‐recognizing double‐stranded oligonucleotide is incorporated as a binding moiety of POI is reported. It is demonstrated that O'PROTACs of lymphoid enhancer‐binding factor 1 (LEF1) and ETS‐related gene (ERG), two highly cancer‐related transcription factors, successfully promote degradation of these proteins, impede their transcriptional activity, and inhibit cancer cell growth in vitro and in vivo. The programmable nature of O'PROTACs indicates that this approach is also applicable to destruct other TFs. O'PROTACs not only can serve as a research tool but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer.
Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease
Wang, Rutao , Serruys, Patrick W. , Gao, Chao , Hara, Hironori , Takahashi, Kuniaki , Ono, Masafumi , Kawashima, Hideyuki , O’Leary, Neil , Holmes, David R. , Curzen, Nick , Geuns, Robert‐Jan van , Morel, Marie‐Angèle , Head, Stuart J., Thuijs, Daniel J.F.M. , Davierwala, Piroze , O’Brien, Timothy , Garg, Scot , Onuma, Yoshinobu , Witkowski, Adam , Curzen, Nick , Burzotta, Francesco , Kappetein, Arie Pieter , Thuijs, Daniel J F M , Garg, Scot , Serruys, Patrick W , Onuma, Yoshinobu , Witkowski, Adam , James, Stefan Karl , Kappetein, A. Pieter , Fuster, Valentı́n

Mayo Clinic

European Heart Journal | August 13, 2021 | Volume: 43 | Issue: 1 | Pages: 56-67

10.1093/eurheartj/ehab441 | PMID 34405232 Get It

Abstract Aims The aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. Methods and results The SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: −7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: −6.5%, 22.5%, P = 0.227). Conclusions The treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials. Trial registration SYNTAX: ClinicalTrials.gov reference: NCT00114972 and SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.
atg7 -Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity
Wang, Yong , Lu, Xiaoguang , Wang, Xiaoping , Qiu, Qi , Zhu, Ping , Ma, Lin , Ma, Xiao , Herrmann, Joerg , Wang, Wei , Lin, Xueying , Ma, Xiao , Xu, Xiaolei

Mayo Clinic

Circulation Research | August 13, 2021 | Volume: 129 | Issue: 8 | Pages: No page available

10.1161/circresaha.121.319104 | PMID 34384247 Get It

Rationale: Anthracycline-induced cardiotoxicity (AIC) is a major side effect that limits the use of anthracyclines as effective chemotherapeutics. No mechanism-based therapy is available when cardiac function deteriorates. Objective: We aim to elucidate the dynamic autophagic defects in AIC and to identify a mechanism-based therapy via both genetic and pharmacological studies. Method and Results: Through phenotyping an adult AIC zebrafish model, we detected a biphasic response in autophagy: activation in the early stage and suppression in the later phase that is characterized by a decline in cardiac function. We conducted conditional genetic studies with atg7 , which encodes a rate-limiting autophagy core protein, and found that atg7 overexpression leads to therapeutic effects in the late phase but deleterious effects in the early phase of adult AIC. We then assessed the therapeutic effects of 37 Food and Drug Administration–approved autophagy activators using an embryonic AIC zebrafish model and identified spironolactone, pravastatin, and minoxidil as top-ranking drugs. We demonstrated the therapeutic efficacy of these Food and Drug Administration–approved autophagy activators in the adult AIC model and confirmed that these drugs exert therapeutic effects in the late phase but not in the early AIC phase. Finally, we demonstrated that the time-dependent therapeutic effects are conserved in a mouse AIC model and that spironolactone and rapamycin activated autophagy in an Atg7-dependent fashion. Conclusions: Our findings suggest that atg7-based autophagy activation is an effective therapeutic avenue to reversing the decline in cardiac function in AIC, highlighting the time-dependent nature of autophagy-based therapy.
EEG Biomarkers of Repository Corticotropin Injection Treatment
Tanritanir, Ahmet, Vieluf, Solveig , Wang, Xiao‐Fan , Jafarpour, Saba, Jafarpour, Saba , Loddenkemper, Tobias , Vieluf, Solveig

Mayo Clinic

Journal of Clinical Neurophysiology | August 13, 2021 | Volume: 40 | Issue: 3 | Pages: 236-243

10.1097/wnp.0000000000000886 | PMID 34387275 Get It

Purpose: Hypsarrhythmia is one of the major diagnostic and treatment response criteria in infantile spasms (IS). The clinical and electrophysiological effect of repository corticotropin injection treatment on IS was evaluated using electrophysiological biomarkers. Methods: Consecutive infants (<24 months) treated with repository corticotropin injection for IS were included in this retrospective descriptive study. Inclusion criteria were (1) clinical IS diagnosis, (2) repository corticotropin injection treatment, and (3) consecutive EEG recordings before and after repository corticotropin injection treatment. Patients with tuberous sclerosis complex were excluded. Response to treatment was defined as freedom from IS for at least 7 consecutive days during the treatment and resolution of hypsarrhythmia. The authors defined “relapse” as the recurrence of seizures after an initial response. Electrophysiological biomarker assessment included evaluation of semiautomatic spike counting algorithm, delta power, and delta coherence calculation during non-REM sleep EEG. Results: One hundred fifty patients (83 males; 55%; median age of IS onset: 5.9 months) with complete data were included, including 101 responders (67%, 71 with sustained response, and 30 relapses). Fifty patients (33%) with complete EEG data also underwent advanced EEG analysis. Baseline delta coherence was higher in sustained responders than in nonresponders or patients who relapsed. Greater decreases in semiautomatic spike counting algorithm, delta power, and delta coherence were found in sustained responders compared with nonresponders or patients who relapsed. Conclusions: Repository corticotropin injection treatment was associated with a 67% response rate in patients with IS. Computational biomarkers beyond hypsarrhythmia may provide additional information during IS treatment, such as early determination of treatment response and outcome assessment.
Peripartum Antibiotics Exposure and the Risk of Autoimmune and Autism Disorders in the Offspring
Almasri, Jehad , Barazi, Ahmed, Walther-António, Marina , Wang, Zhen , Absah, Imad , King, Katherine S. , Walther-Antonio, Marina R S, Murad, Mohammad H, Walther-Antonio, Marina , Murad, M. Hassan , Murray, Joseph A.

Mayo Clinic

Avicenna Journal of Medicine | August 12, 2021 | Volume: 11 | Issue: 03 | Pages: 118-125

10.1055/s-0041-1732485 | PMID 34646788 Get It

Abstract Background As the use of antibiotics during the peripartum period increases, the incidence of autoimmune disorders and autism spectrum disorders (ASDs) is also increasing. In this study, we aim to assess if antibiotic exposure during the peripartum period affects the incidence of autoimmune diseases and ASD in the offspring. Methods We identified children (< 18 years of age) born in Olmsted County from January 1, 2003 through December 31, 2012. Offspring with celiac disease (CD), inflammatory bowel disease (IBD), or ASD diagnoses were matched to two controls on birth date, index date, mother’s age at delivery, and sex. Data from the mother’s medical records were retrieved to determine peripartum antibiotics use. Results A total of 242 cases and 484 matched controls were included in this study. Median age at the last follow-up was 11.3 years (range: 0.5–14.9), 73% were males in both groups. Odds of CD diagnosis was not statistically different between vaginal delivery with antibiotics compared with vaginal delivery with no antibiotics (odds ratio [OR] = 0.76, 95% confidence interval [CI]: 0.32–1.85), similarly in IBD (OR = 2.41, 95% CI: 0.53–10.98) and ASD (OR = 1.00, 95% CI:0.55–1.79). Preeclampsia or eclampsia was associated with offspring CD (OR = 3.20, 95% CI: 1.05–9.78). Smoking history and diabetes mellitus were associated with offspring ASD (OR = 1.84, 95% CI: 1.22–2.77 and OR = 2.01, 95% CI: 1.03–3.91, respectively). Conclusion In this cohort, we found no statistically significant association between peripartum antibiotics exposure and the development of CD, IBD, or ASD.
Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS
Vivekanandhan, Sneha , Madamsetty, Vijay Sagar , Dutta, Shamit K., Wang, Enfeng , Caulfield, Thomas R. , Pletnev, Alexandre A., Asmann, Yan W. , Chang, David K. , Spaller, Mark R., Mukhopadhyay, Debabrata , Madamsetty, Vijay S , Angom, Ramcharan Singh , Dutta, Shamit Kumar, Caulfield, Thomas R , Chang, David , Mukhopadhyay, Debabrata , Upstill-Goddard, Rosanna

Mayo Clinic

Cancers | August 11, 2021 | Volume: 13 | Issue: 16 | Pages: 4048

10.3390/cancers13164048 | PMID 34439202 Get It

PLEXIND1 is upregulated in several cancers, including pancreatic ductal adenocarcinoma (PDAC). It is an established mediator of semaphorin signaling, and neuropilins are its known coreceptors. Herein, we report data to support the proposal that PLEXIND1 acts as a transforming growth factor beta (TGFβ) coreceptor, modulating cell growth through SMAD3 signaling. Our findings demonstrate that PLEXIND1 plays a pro-tumorigenic role in PDAC cells with oncogenic KRAS (KRASmut). We show in KRASmut PDAC cell lines (PANC-1, AsPC-1,4535) PLEXIND1 downregulation results in decreased cell viability (in vitro) and reduced tumor growth (in vivo). Conversely, PLEXIND1 acts as a tumor suppressor in the PDAC cell line (BxPC-3) with wild-type KRAS (KRASwt), as its reduced expression results in higher cell viability (in-vitro) and tumor growth (in vivo). Additionally, we demonstrate that PLEXIND1-mediated interactions can be selectively disrupted using a peptide based on its C-terminal sequence (a PDZ domain-binding motif), an outcome that may possess significant therapeutic implications. To our knowledge, this is the first report showing that (1) PLEXIND1 acts as a TGFβ coreceptor and mediates SMAD3 signaling, and (2) differential roles of PLEXIND1 in PDAC cell lines correlate with KRASmut and KRASwt status.
Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China
Tian, Panwen , Qiu, Rong , Xu, Shufeng , Wang, Meifang , Cao, Liming , Yang, Ping , Li, Weimin

Mayo Clinic

JAMA Network Open | August 10, 2021 | Volume: 4 | Issue: 8 | Pages: e2120306

10.1001/jamanetworkopen.2021.20306 | PMID 34374774 Get It

Timing and durability of response to erenumab in patients with chronic migraine
Tepper, Stewart J. , Lucas, Sylvia , Scanlon, James, Klatt, Jan , Chou, Denise E. , Wang, Andrea , Ashina, Messoud , Ashina, Messoud , Schwedt, Todd J. , Ailani, Jessica , Lima, Gabriel Paiva da Silva

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 7, 2021 | Volume: 61 | Issue: 8 | Pages: 1255-1263

10.1111/head.14193 | PMID 34363708 Get It

Abstract Background Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response. Methods This is a post hoc analysis of a 12‐week, randomized, double‐blind, placebo‐controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%). Results Among the erenumab 140 mg group ( n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group ( n = 188). Conclusion A majority of erenumab‐treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report
Benjamin, Emelia J. , Al‐Khatib, Sana M. , Desvigne‐Nickens, Patrice , Alonso, Álvaro , Djoussé, Luc , Forman, Daniel E. , Gillis, Anne M. , Hendriks, Jeroen , Hills, Mellanie True , Kirchhof, Paulus , Marcus, Gregory M. , Murray, Katherine T. , Parkash, Ratika , Redline, Susan , Rienstra, Michiel , Wang, Paul J. , Cooper, Lawton S. , Go, Alan S. , Alonso, Alvaro , Kirchhof, Paulus , True Hills, Mellanie , Rienstra, Michiel , Benjamin, Emelia J , Hendriks, Jeroen M , Marcus, Gregory M , Forman, Daniel Edward , Link, Mark S. , Mehra, Reena , Piña, Ileana L. , Sanders, Prashanthan , Somers, Virend K. , Wagoner, David R. Van , Al-Khatib, Sana M.

Mayo Clinic

Journal of the American Heart Association | August 5, 2021 | Volume: 10 | Issue: 16 | Pages: No page available

10.1161/jaha.121.021566 | PMID 34351783 Get It

There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF‐related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced‐based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF‐related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team‐based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
Characterizing phenotypic abnormalities associated with high-risk individuals developing lung cancer using electronic health records from the All of Us researcher workbench
Zong, Nansu , Midthun, David E. , Jiang, Guoqian , Na, Jie , Wang, Chen , Luo, Yuan , Yang, Ping

Mayo Clinic

Journal of the American Medical Informatics Association | August 4, 2021 | Volume: 28 | Issue: 11 | Pages: 2313-2324

10.1093/jamia/ocab174 | PMID 34505903 Get It

Abstract Objective The study sought to test the feasibility of conducting a phenome-wide association study to characterize phenotypic abnormalities associated with individuals at high risk for lung cancer using electronic health records. Materials and Methods We used the beta release of the All of Us Researcher Workbench with clinical and survey data from a population of 225 000 subjects. We identified 3 cohorts of individuals at high risk to develop lung cancer based on (1) the 2013 U.S. Preventive Services Task Force criteria, (2) the long-term quitters of cigarette smoking criteria, and (3) the younger age of onset criteria. We applied the logistic regression analysis to identify the significant associations between individuals’ phenotypes and their risk categories. We validated our findings against a lung cancer cohort from the same population and conducted an expert review to understand whether these associations are known or potentially novel. Results We found a total of 214 statistically significant associations (P &lt; .05 with a Bonferroni correction and odds ratio &gt; 1.5) enriched in the high-risk individuals from 3 cohorts, and 15 enriched in the low-risk individuals. Forty significant associations enriched in the high-risk individuals and 13 enriched in the low-risk individuals were validated in the cancer cohort. Expert review identified 15 potentially new associations enriched in the high-risk individuals. Conclusions It is feasible to conduct a phenome-wide association study to characterize phenotypic abnormalities associated in high-risk individuals developing lung cancer using electronic health records. The All of Us Research Workbench is a promising resource for the research studies to evaluate and optimize lung cancer screening criteria.